Enterprise Value

3.981B

Cash

786M

Avg Qtr Burn

-127.1M

Short % of Float

9.64%

Insider Ownership

1.29%

Institutional Own.

-

Qtr Updated

09/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
ARIKAYCE (Amikacin Liposome Inhalation Suspension) Details
Mycobacterium avium complex lung disease, Nontuberculous mycobacterial lung disease

Approved

Update

Brensocatib (DPP1 inhibitor) Details
Non-Cystic Fibrosis Bronchiectasis

Phase 3

Data readout

Phase 2

Interim update

Phase 2

Interim update

Phase 2

Update

Phase 2

Initiation